What is a desmoid tumour?
A desmoid tumour, also called aggressive fibromatosis or desmoid-type fibromatosis, is a rare growth of fibrous (connective) tissue. It starts from fibroblast-like cells in muscles, the sheets of tissue around muscles (fascia), or the tissue that holds the bowel in place (the mesentery).
Desmoid tumours are not cancer in the usual sense: they do not spread to other parts of the body. However, they can grow into nearby muscles, nerves, blood vessels and organs, and they often come back after surgery. For this reason the WHO Classification of Soft Tissue and Bone Tumours (5th edition, 2020) places them in the “intermediate, locally aggressive” group, between benign and malignant tumours.
Their behaviour is hard to predict. Some grow steadily, some stay the same size for years, and about a quarter shrink or disappear on their own. This is why treatment has changed: most people now start with careful monitoring rather than immediate surgery.
1. How common is it?
| Feature | Details |
|---|---|
| New cases | About 3-5 per million people each year |
| Age | Usually 15-60; peak at about 30-40; can occur in children |
| Sex | About twice as common in women, especially during or after pregnancy |
| Abdominal wall | Common in young women, often during or soon after pregnancy |
| Inside the abdomen | Often in the mesentery; more common in people with familial adenomatous polyposis (FAP) |
| Elsewhere | Shoulder, chest wall, back, buttock, thigh, and head and neck |
Desmoid tumours account for only about 0.03% of all tumours. Because they are so rare, people should be treated at, or in contact with, a specialist sarcoma centre.
2. Causes and risk factors
Desmoid tumours are caused by changes in the WNT/beta-catenin signalling pathway, which controls how cells grow and repair tissue. Two main types are recognised by their cause.
| Type | Cause | Share of cases | Features |
|---|---|---|---|
| Sporadic | A change in the CTNNB1 gene (beta-catenin) in the tumour cells only; not inherited | About 85-90% | Most common types are T41A, S45F and S45P. Tumours with S45F may be more likely to come back after surgery |
| FAP-related | An inherited change in the APC gene | About 5-15% | People with FAP have a lifetime risk of desmoid tumours of about 10-25%. Tumours are often inside the abdomen and may be multiple |
Other factors that seem to trigger growth include:
- Injury or surgery: many tumours start in a scar, for example after a caesarean section or bowel surgery.
- Pregnancy and oestrogen: tumours of the abdominal wall often appear during or after pregnancy.
People whose tumour has no CTNNB1 mutation, or who have a tumour inside the abdomen or a family history of bowel polyps, are usually offered testing for FAP. This means a colonoscopy and, where appropriate, a blood test for APC changes.
3. How does it look?
3.1 On the body
A desmoid tumour usually feels like a firm, rubbery or hard lump deep under the skin. It is fixed to the muscle beneath and does not move freely. The skin over it normally looks normal.
| Site | What may be noticed |
|---|---|
| Abdominal wall | A firm lump in the muscles of the tummy, often near a caesarean or other surgical scar |
| Shoulder, chest wall, back, buttock or thigh | A slowly growing deep lump, sometimes very large, that may limit movement |
| Inside the abdomen | Often nothing can be seen; a large tumour may make the tummy swell or be felt as a hard mass |
| Head and neck | A firm swelling in the neck or face; in children, this area is affected more often |
3.2 On scans
MRI with contrast is the best scan for tumours in the limbs and trunk. CT is often used for tumours inside the abdomen.
| Feature | Typical appearance |
|---|---|
| Shape | Oval or irregular mass, often spreading along the fascia |
| “Fascial tail” sign | A thin extension along the muscle sheath at the edges of the tumour |
| Bands of collagen | Dark bands on T2-weighted MRI where dense fibrous tissue is present |
| Signal over time | Tumours that are becoming more fibrous and less active turn darker on T2 images, which often goes with shrinkage or stability |
| Mesenteric tumours on CT | Soft tissue mass in the mesentery, sometimes wrapping around blood vessels or bowel |
3.3 Under the microscope
| Feature | Description |
|---|---|
| Cells | Long, uniform spindle cells with small, bland nuclei, arranged in long sweeping bundles |
| Background | Plenty of collagen (fibrous tissue) and thin-walled blood vessels |
| Edges | Infiltrate into surrounding muscle and fat; no capsule |
| Key stain | Nuclear beta-catenin is present in most tumours and supports the diagnosis |
| Molecular test | Testing for CTNNB1 mutations confirms the diagnosis in difficult cases |
The diagnosis should be confirmed by a pathologist with sarcoma experience, because desmoid tumours can look like scar tissue or like other soft tissue tumours.
4. Symptoms
Many desmoid tumours cause few or no symptoms and are found as a painless lump. Others cause pain or problems with movement or with nearby organs. Symptoms depend mainly on where the tumour is.
| Site | Common symptoms |
|---|---|
| Limbs, shoulder and trunk | A growing lump; aching or sharp pain; stiffness or reduced movement of a joint; tingling, numbness or weakness if a nerve is pressed |
| Abdominal wall | A lump that is often painless; discomfort when bending or tightening the tummy muscles |
| Inside the abdomen | Tummy pain or swelling, feeling full quickly, nausea, change in bowel habit; sometimes no symptoms until the tumour is large |
| Head and neck | Swelling; difficulty swallowing or breathing if large; pain or nerve problems |
Serious complications
Tumours inside the abdomen can cause emergencies, especially in people with FAP:
- Bowel blockage: cramping pain, vomiting, swollen tummy, not passing wind or stools.
- Blocked ureter: the tube from the kidney is squeezed, which can cause back pain and kidney damage, sometimes without symptoms.
- Bowel perforation or bleeding (rare).
- Fistula: an abnormal channel between the bowel and the skin or another organ (rare).
See a doctor urgently for severe or increasing tummy pain, vomiting, inability to pass stools, a rapidly growing lump, or new weakness or numbness in a limb.
Any deep lump larger than 5 cm, or one that is growing, should be checked by a doctor and, if needed, referred to a sarcoma centre. Although desmoid tumours are not cancer, these features can also be signs of a soft tissue sarcoma.
5. Diagnosis
| Test | Purpose |
|---|---|
| MRI or CT scan | Shows the size, exact position and relation to nerves, vessels and organs; used later to monitor growth |
| Core needle biopsy | Needed for the diagnosis; taken with ultrasound or CT guidance. Removing the lump without a biopsy is not recommended |
| Beta-catenin stain and CTNNB1 testing | Confirm the diagnosis and suggest whether the tumour is sporadic |
| Colonoscopy and APC testing | Look for FAP, especially if there is no CTNNB1 mutation, the tumour is inside the abdomen or there is a family history |
| Kidney scan or blood tests | For abdominal tumours, check the ureters and kidney function |
Desmoid tumours do not spread, so there is no staging system like that used for cancers. Doctors describe the tumour by site, size, symptoms and whether it is growing.
6. Treatment
The global consensus guideline of the Desmoid Tumor Working Group (2020) and the ESMO-EURACAN-GENTURIS guidelines recommend that treatment is planned by a specialist sarcoma team. The main principle is that most people should start with active surveillance, because many tumours stop growing or shrink without treatment.
6.1 Active surveillance
| Aspect | Details |
|---|---|
| Who it suits | Most newly diagnosed people whose tumour is not causing serious problems or threatening an organ |
| What it involves | An MRI or CT scan about 1-2 months after diagnosis, then every 3-6 months in the first years, then less often |
| Outcome | About half of tumours never need active treatment; about 20-30% shrink on their own |
| When to start treatment | Clear growth on several scans in a row, worsening symptoms, or a risk to vital structures |
| Pain relief | Simple painkillers or anti-inflammatory medicines can be used during monitoring |
6.2 Medicines
Drug treatment is now the usual first active treatment for tumours that are growing or causing symptoms, especially when surgery would cause disability.
| Treatment | How it works | How it is given | Benefit in trials | Common side effects |
|---|---|---|---|---|
| Nirogacestat | Gamma-secretase inhibitor that blocks Notch signalling | Tablet twice daily | DeFi trial: risk of progression reduced by about 70% versus placebo; tumours shrank in 41% versus 8% | Diarrhoea, nausea, tiredness, rash, mouth sores; in women, ovarian function often stops temporarily |
| Sorafenib | Tyrosine kinase inhibitor | Tablet once daily | 2-year progression-free survival 81% versus 36% with placebo; tumours shrank in 33% | Rash, hand-foot skin reaction, tiredness, high blood pressure, diarrhoea |
| Pazopanib | Tyrosine kinase inhibitor | Tablet once daily | DESMOPAZ: 84% free of progression at 6 months, versus 45% with methotrexate-vinblastine | High blood pressure, diarrhoea, liver changes, hair colour change |
| Low-dose chemotherapy (methotrexate with vinblastine or vinorelbine) | Slows cell division | Weekly injections or tablets for about 1 year | Disease control in most people; slow responses | Tiredness, low blood counts, nerve tingling; often used in children |
| Doxorubicin-based chemotherapy | Stronger chemotherapy | Drip every 3 weeks | Faster shrinkage | Hair loss, low blood counts, heart effects; kept for fast-growing or dangerous tumours |
| Anti-inflammatory and hormone tablets (e.g. sulindac, tamoxifen) | Uncertain | Tablets | Limited evidence; no longer recommended as standard | Stomach upset (NSAIDs); hot flushes and clot risk (tamoxifen) |
Nirogacestat was approved in the USA in November 2023 and in the European Union in August 2025 for adults with progressing desmoid tumours who need systemic treatment. It is the first medicine approved specifically for desmoid tumours.
6.3 Surgery
Surgery used to be the main treatment, but local recurrence is common: about 20-30% of tumours come back after removal, and more in the limbs and in people with S45F mutations. Large French and Italian studies showed that, for many people, starting with surveillance gives the same long-term results.
| When surgery may be chosen | Points to know |
|---|---|
| Abdominal wall tumours that keep growing | Recurrence after surgery is relatively low at this site, and removal is usually straightforward |
| Tumours that do not respond to medicines | Planned by an experienced sarcoma surgeon; function is protected where possible |
| Emergencies | Bowel blockage or perforation from an abdominal tumour |
| Margins | Surgeons aim for a clear edge, but damaging surgery is avoided because a positive margin does not always lead to regrowth |
6.4 Radiotherapy and local treatments
| Treatment | Use | Points to know |
|---|---|---|
| Radiotherapy (about 50-56 Gy over 5-6 weeks) | Growing tumours in the limbs or trunk when surgery and medicines are not suitable | Controls the tumour in about 70-80%; avoided in young people where possible because of long-term risks, including a small risk of a new cancer |
| Cryoablation | Freezing the tumour through a needle under image guidance; used for limb and trunk tumours | Good control in early studies; can be repeated |
| High-intensity focused ultrasound (HIFU) | Heating with focused ultrasound in selected centres | Still being studied |
6.5 Tumours in people with FAP
In people with FAP, desmoid tumours inside the abdomen are one of the main causes of serious illness and death after the bowel has been removed. Surgery on mesenteric tumours is risky and often avoided. Treatment usually starts with medicines, and close teamwork between the polyposis clinic and the sarcoma centre is important.
7. Outlook
Desmoid tumours do not spread to distant organs, and most people have a normal life expectancy. The main challenges are pain, reduced function, and the need for long-term follow-up.
| Situation | Typical outcome |
|---|---|
| Tumour on active surveillance | About half never need treatment; growth, if it happens, is usually in the first 1-2 years |
| Abdominal wall tumour | Often stabilises or shrinks; good results with surgery if needed |
| Limb or trunk tumour | May affect movement; medicines, radiotherapy or cryoablation usually control it |
| Mesenteric tumour in FAP | The most serious form; can block the bowel or ureters; long-term care in a specialist centre |
| Death from desmoid tumour | Rare, almost always from tumours inside the abdomen or in the head and neck that press on vital structures |
8. Living with a desmoid tumour
- Uncertainty is common. Monitoring can feel like “doing nothing”, but it is an active, evidence-based choice that avoids unnecessary surgery.
- Pregnancy: having had a desmoid tumour is not a reason to avoid pregnancy. Tumours may grow during pregnancy but often shrink afterwards. Discuss plans with your specialist team.
- Physiotherapy can help keep joints moving and reduce pain.
- Pain management may include simple painkillers, nerve pain medicines, or referral to a pain clinic.
- Fertility should be discussed before nirogacestat or chemotherapy.
- Patient organisations such as the Desmoid Tumor Research Foundation and Sarcoma UK provide information and support.
9. Frequently asked questions
| Question | Answer |
|---|---|
| Is a desmoid tumour cancer? | It is not a cancer in the usual sense, because it does not spread. It is treated in sarcoma centres because it can grow into nearby tissues |
| Why would doctors watch a tumour instead of removing it? | Many tumours stop growing or shrink, and surgery often leads to recurrence. Monitoring avoids unnecessary operations |
| Will it come back after treatment? | It can. Recurrence is more common after surgery in the limbs. Regular scans help to find regrowth early |
| Is it inherited? | Most are not. About 1 in 10 are linked to FAP, which is inherited, so testing is often offered |
| Can I exercise? | Usually yes. Ask your team about any activities that may strain the area |
Resources
- WHO Classification of Tumours Editorial Board (2020) Soft Tissue and Bone Tumours. 5th edn. Lyon: International Agency for Research on Cancer.
- Desmoid Tumor Working Group (2020) ‘The management of desmoid tumours: a joint global consensus-based guideline approach for adult and paediatric patients’, European Journal of Cancer, 127, pp. 96-107.
- Gronchi, A. et al. (2021) ‘Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 32(11), pp. 1348-1365.
- Kasper, B. et al. (2017) ‘An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and EORTC/Soft Tissue and Bone Sarcoma Group (STBSG)’, Annals of Oncology, 28(10), pp. 2399-2408.
- Lazar, A.J. et al. (2008) ‘Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors’, American Journal of Pathology, 173(5), pp. 1518-1527.
- Fiore, M. et al. (2009) ‘Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment’, Annals of Surgical Oncology, 16(9), pp. 2587-2593.
- Bonvalot, S. et al. (2013) ‘Spontaneous regression of primary abdominal wall desmoid tumors: more common than previously thought’, Annals of Surgical Oncology, 20(13), pp. 4096-4102.
- Penel, N. et al. (2017) ‘Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: a nationwide prospective cohort from the French Sarcoma Group’, European Journal of Cancer, 83, pp. 125-131.
- Gounder, M.M. et al. (2018) ‘Sorafenib for advanced and refractory desmoid tumors’, New England Journal of Medicine, 379(25), pp. 2417-2428.
- Toulmonde, M. et al. (2019) ‘Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study’, Lancet Oncology, 20(9), pp. 1263-1272.
- Gounder, M. et al. (2023) ‘Nirogacestat, a gamma-secretase inhibitor for desmoid tumors’, New England Journal of Medicine, 388(10), pp. 898-912.
- National Cancer Institute (2026) Desmoid Tumor. Available at: https://www.cancer.gov/pediatric-adult-rare-tumor/rare-tumors/rare-soft-tissue-tumors/desmoid-tumor (Accessed: October 2026).
- Desmoid Tumor Research Foundation (2026) About desmoid tumors. Available at: https://dtrf.org/ (Accessed: October 2026).
Prepared by the editorial team, October 2026.